alloxan has been researched along with Autoimmune Diabetes in 79 studies
Alloxan: Acidic compound formed by oxidation of URIC ACID. It is isolated as an efflorescent crystalline hydrate.
alloxan : A member of the class of pyrimidones, the structure of which is that of perhydropyrimidine substituted at C-2, -4, -5 and -6 by oxo groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated whether increases in the duration of hyperglycemia result in the development of corneal lesions in a mouse model of alloxan (AL)- or streptozotocin (STZ)-induced type 1 diabetes." | 7.88 | Extended Duration of Hyperglycemia Result in Human-Like Corneal Nerve Lesions in Mice With Alloxan- and Streptozotocin-Induced Type 1 Diabetes. ( Matsuura, T; Ozaki, K; Terayama, Y, 2018) |
| "Alloxan and oxidative stress, which have been detected in livers of laboratory animals shortly after in vivo alloxan administration, cause in vitro mitochondrial dysfunction, thus questioning alloxan diabetes as an acceptable model for type 1 diabetes, a model that cannot legitimately be used to investigate mitochondrial metabolism in a diabetic state." | 7.77 | Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes? ( Alvarez-Bustamante, JA; Rendon, DA, 2011) |
| "To compare the contact lens-induced corneal edema recovery dynamics of human subjects with type 1 diabetes with those of age- and sex-matched normal human subjects; to compare the human data with previously reported data from alloxan-induced diabetic rabbit." | 7.69 | Corneal edema recovery dynamics in diabetes: is the alloxan induced diabetic rabbit a useful model? ( Herse, P; Hooker, B, 1994) |
| " The current study investigates protection against the hyperglycemia and dyslipidemia in alloxan-induced (type I diabetes) and fructose-fed insulin resistance (type II diabetes) models of diabetes treated with aqueous methanolic root extract of E." | 3.91 | Antidiabetic and antidyslipidemic potential of Echinops echinatus in rat models of type I and type II diabetes. ( Akram, A; Aslam, N; Chaudhry, SRY; Iqbal, Z; Jabeen, Q; Muhammad, S; Nazir, I; Wajid, M, 2019) |
| " We investigated whether increases in the duration of hyperglycemia result in the development of corneal lesions in a mouse model of alloxan (AL)- or streptozotocin (STZ)-induced type 1 diabetes." | 3.88 | Extended Duration of Hyperglycemia Result in Human-Like Corneal Nerve Lesions in Mice With Alloxan- and Streptozotocin-Induced Type 1 Diabetes. ( Matsuura, T; Ozaki, K; Terayama, Y, 2018) |
| " Body weight, fasting blood glucose, hepatic glycogen, serum insulin, and serum glucagon were determined by electronic scales, glucometer, and ELISA kits." | 3.85 | Formononetin exhibits anti-hyperglycemic activity in alloxan-induced type 1 diabetic mice. ( Chen, J; Fu, H; Huan, M; Qiu, G; Tian, W, 2017) |
| " Type 1 diabetes was induced in C57Bl/6, NMRI, BALB/c, and 129Sv mice by alloxan, and conscious glomerular filtration rate, proteinuria, and oxidative stress levels were measured in control and diabetic animals at baseline and after 5 and 10 wk." | 3.80 | Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes. ( Fasching, A; Franzén, S; Friederich-Persson, M; Hansell, P; Nangaku, M; Palm, F, 2014) |
| "Alloxan and oxidative stress, which have been detected in livers of laboratory animals shortly after in vivo alloxan administration, cause in vitro mitochondrial dysfunction, thus questioning alloxan diabetes as an acceptable model for type 1 diabetes, a model that cannot legitimately be used to investigate mitochondrial metabolism in a diabetic state." | 3.77 | Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes? ( Alvarez-Bustamante, JA; Rendon, DA, 2011) |
| " Pretreatment with PBN (150 mg/kg ip) significantly reduced the severity of hyperglycemia in both alloxan- and streptozotocin (STZ) induced diabetes." | 3.70 | Alpha-phenyl-tert-butylnitrone (PBN) inhibits NFkappaB activation offering protection against chemically induced diabetes. ( Bray, TM; Chen, G; Ho, E, 2000) |
| "To compare the contact lens-induced corneal edema recovery dynamics of human subjects with type 1 diabetes with those of age- and sex-matched normal human subjects; to compare the human data with previously reported data from alloxan-induced diabetic rabbit." | 3.69 | Corneal edema recovery dynamics in diabetes: is the alloxan induced diabetic rabbit a useful model? ( Herse, P; Hooker, B, 1994) |
| "Basic Protocol: Induction of type I diabetes mellitus in beagle dogs using alloxan and streptozotocin." | 1.72 | Induction of Type I Diabetes Mellitus in Beagle Dogs Using Alloxan and Streptozotocin. ( Araujo, J; de Rivera, C; Mendes, J; Paradis, A; Petrik, S, 2022) |
| " The oral pharmacological bioavailability of the nanoparticles in type I diabetic mice was 12." | 1.62 | Insulin- and cholic acid-loaded zein/casein-dextran nanoparticles enhance the oral absorption and hypoglycemic effect of insulin. ( Bao, X; Qian, K; Yao, P, 2021) |
| "The health conditions of the rats with Type 1 diabetes were significantly enhanced after treatment with MTSE/ZnO/Ag (p < 0." | 1.56 | Biogenic integrated ZnO/Ag nanocomposite: Surface analysis and in vivo practices for the management of type 1 diabetes complications. ( Abdul Raman, AA; Bayrami, A; Chae, KH; Darvishi Cheshmeh Soltani, R; Habibi-Yangjeh, A; Kang, HK; Khataee, A; Mohammadi Arvanag, F; Rahim Pouran, S; Singh, R, 2020) |
| "Inflammation is involved in diabetes-related vascular dysfunction." | 1.51 | Involvement of inducible nitric oxide synthase and estrogen receptor ESR2 (ERβ) in the vascular dysfunction in female type 1 diabetic rats. ( Akamine, EH; Carvalho, MHC; Ceravolo, GS; Costa, BP; Fortes, ZB; Santos, FF; Santos-Eichler, R; Sartoretto, SM, 2019) |
| "Ketamine was shown to be capable of increasing the activity of acetylcholinesterase (AChE) in the brain structures." | 1.46 | Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia. ( Canever, L; Damiani, AP; de Andrade, VM; Fachim, I; Gomes, ST; Gress, K; Heylmann, ASA; Mastella, GA; Michels, C; Quevedo, J; Steckert, AV; Stopassoli, GC; Zugno, AI, 2017) |
| "Aortic banding was used to provoke arrhythmia." | 1.42 | Functional role of myocardial electrical remodeling in diabetic rabbits. ( Arteyeva, NV; Azarov, JE; Ovechkin, AO; Sedova, K; Shumikhin, KV; Vaykshnorayte, MA, 2015) |
| "A common complication of type 1 diabetes mellitus is diabetic ketoacidosis (DKA), a state of severe insulin deficiency." | 1.42 | Simulated diabetic ketoacidosis therapy in vitro elicits brain cell swelling via sodium-hydrogen exchange and anion transport. ( Cepinskas, G; Chan, M; Drysdale, TA; Fraser, DD; Rose, KL; Rupar, CA; Watson, AJ, 2015) |
| "Women with type 1 diabetes are subfertile." | 1.36 | Maternal diabetes impairs gastrulation and insulin and IGF-I receptor expression in rabbit blastocysts. ( Fischer, B; Fischer, S; Navarrete Santos, A; Ramin, N; Schindler, M; Schmidt, T; Thieme, R, 2010) |
| "Impaired vasodilation in type 1 diabetes correlates with enhanced VSM MLC phosphorylation." | 1.35 | Impaired coronary microvascular dilation correlates with enhanced vascular smooth muscle MLC phosphorylation in diabetes. ( Bianchi, C; Boodhwani, M; Clements, RT; Feng, J; Khabbaz, KR; Liu, Y; Mieno, S; Sellke, FW; Sodha, NR, 2009) |
| "In alloxan-treated mice (a model of type 1 diabetes), drugs were administered orally once daily for 6 days post-alloxan treatment." | 1.35 | Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment. ( Jiang, J; Larrick, JW; Wang, Y; Yu, P; Zeng, X; Zhang, Z, 2009) |
| "Alloxan is a classical diabetogen which is used to achieve beta-cell destruction and type 1 diabetes due to its selective cytotoxic effect on pancreatic beta-cells." | 1.35 | Hepatic glucokinase activity is the primary defect in alloxan-induced diabetes of mice. ( Li, H; Liang, W; Mao, Y; Tan, H; Yang, Y; Zhang, X, 2009) |
| " Alloxan-streptozotocin combination administration reduced the dosage of each drug, and decreased the toxic and side effect of each drug." | 1.31 | [Chemically induced (streptozotocin-alloxan) diabetes mellitus in dogs]. ( Liu, S; Luo, XM; Wang, W; Ye, B, 2000) |
| "Alloxan is a well-known and universally used agent for evoking experimental diabetes through its toxic effect on the B cells of the Langerhans islets." | 1.29 | Blood levels of alloxan in children with insulin-dependent diabetes mellitus. ( Chmara, E; Kiełczewska-Mrozikiewicz, D; Korzeniowska, K; Lowicki, Z; Mrozikiewicz, A; Mrozikiewicz, PM, 1994) |
| " The best known diabetogenic substances, Streptozotocin and Alloxan are described, including their usage, dosage dosing intervals, and mechanism of action." | 1.29 | [Experimental models in research of the pathomechanism of diabetes mellitus]. ( Fehér, J; Prechl, J; Pusztai, P; Somogyi, A; Szaleczky, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (11.39) | 18.7374 |
| 1990's | 9 (11.39) | 18.2507 |
| 2000's | 17 (21.52) | 29.6817 |
| 2010's | 28 (35.44) | 24.3611 |
| 2020's | 16 (20.25) | 2.80 |
| Authors | Studies |
|---|---|
| Samidurai, A | 1 |
| Ockaili, R | 1 |
| Cain, C | 1 |
| Roh, SK | 1 |
| Filippone, SM | 1 |
| Kraskauskas, D | 1 |
| Kukreja, RC | 1 |
| Das, A | 1 |
| Arif, B | 1 |
| Arif, Z | 1 |
| Ahmad, J | 1 |
| Perveen, K | 1 |
| Bukhari, NA | 1 |
| Ashraf, JM | 1 |
| Alam, K | 1 |
| Wu, M | 1 |
| Carballo-Jane, E | 1 |
| Zhou, H | 1 |
| Zafian, P | 1 |
| Dai, G | 1 |
| Liu, M | 1 |
| Lao, J | 1 |
| Kelly, T | 1 |
| Shao, D | 1 |
| Gorski, J | 1 |
| Pissarnitski, D | 1 |
| Kekec, A | 1 |
| Chen, Y | 2 |
| Previs, SF | 1 |
| Scapin, G | 1 |
| Llorente, YG | 1 |
| Hollingsworth, SA | 1 |
| Yan, L | 1 |
| Feng, D | 1 |
| Huo, P | 1 |
| Walford, G | 1 |
| Erion, MD | 1 |
| Kelley, DE | 1 |
| Lin, S | 1 |
| Mu, J | 1 |
| Das, M | 1 |
| Banerjee, A | 1 |
| Roy, R | 1 |
| Huang, R | 1 |
| Lu, Y | 1 |
| Xie, Z | 1 |
| Yang, X | 1 |
| Ou, Y | 1 |
| Araujo, J | 1 |
| Paradis, A | 1 |
| Mendes, J | 1 |
| Petrik, S | 1 |
| de Rivera, C | 1 |
| Ramírez-Moreno, A | 1 |
| Quintanar Escorza, MA | 1 |
| García Garza, R | 1 |
| Hady, K | 1 |
| Meléndez Valenzuela, A | 1 |
| Marszalek, JE | 1 |
| Sharara-Núñez, I | 1 |
| Delgadillo-Guzmán, D | 1 |
| Sanad, FA | 1 |
| Ahmed, SF | 1 |
| El-Tantawy, WH | 2 |
| Rahim Pouran, S | 1 |
| Bayrami, A | 1 |
| Mohammadi Arvanag, F | 1 |
| Habibi-Yangjeh, A | 1 |
| Darvishi Cheshmeh Soltani, R | 1 |
| Singh, R | 1 |
| Abdul Raman, AA | 1 |
| Chae, KH | 1 |
| Khataee, A | 1 |
| Kang, HK | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Zhou, Y | 1 |
| Cai, M | 1 |
| Lin, K | 1 |
| Fang, B | 1 |
| Xia, L | 1 |
| Schindler, M | 6 |
| Dannenberger, D | 1 |
| Nuernberg, G | 1 |
| Pendzialek, M | 3 |
| Grybel, K | 1 |
| Seeling, T | 2 |
| Navarrete Santos, A | 5 |
| Xie, K | 1 |
| Zhang, X | 2 |
| Sui, S | 1 |
| Ye, F | 1 |
| Dai, J | 1 |
| Miranda, LMO | 1 |
| Agostini, LDC | 1 |
| Lima, WG | 1 |
| Camini, FC | 1 |
| Costa, DC | 1 |
| Azmi, MB | 1 |
| Qureshi, SA | 1 |
| Haseen Ahmed, SD | 1 |
| Khan, AA | 1 |
| Ahsan, M | 1 |
| Mudassir, HA | 1 |
| Imtiaz, F | 1 |
| Rais, S | 1 |
| Bao, X | 1 |
| Qian, K | 1 |
| Yao, P | 1 |
| Grybel, KJ | 1 |
| Gürke, J | 2 |
| Fischer, B | 5 |
| Xiao, X | 1 |
| Guo, P | 1 |
| Shiota, C | 1 |
| Zhang, T | 1 |
| Coudriet, GM | 1 |
| Fischbach, S | 1 |
| Prasadan, K | 1 |
| Fusco, J | 1 |
| Ramachandran, S | 1 |
| Witkowski, P | 1 |
| Piganelli, JD | 1 |
| Gittes, GK | 1 |
| Živadinović, M | 1 |
| Andrić, M | 1 |
| Milošević, V | 1 |
| Manojlović-Stojanoski, M | 1 |
| Prokić, B | 2 |
| Dimić, A | 1 |
| Ćalasan, D | 1 |
| Brković, B | 1 |
| Chaudhry, SR | 1 |
| Akram, A | 2 |
| Aslam, N | 2 |
| Asif, M | 1 |
| Wajid, M | 2 |
| Kinfe, T | 1 |
| Jabeen, Q | 2 |
| Muhammad, S | 2 |
| Sartoretto, SM | 1 |
| Santos, FF | 1 |
| Costa, BP | 1 |
| Ceravolo, GS | 1 |
| Santos-Eichler, R | 1 |
| Carvalho, MHC | 1 |
| Fortes, ZB | 1 |
| Akamine, EH | 1 |
| Ozaki, K | 1 |
| Terayama, Y | 1 |
| Matsuura, T | 1 |
| Pashapoor, A | 1 |
| Mashhadyrafie, S | 1 |
| Mortazavi, P | 1 |
| Chaudhry, SRY | 1 |
| Iqbal, Z | 1 |
| Nazir, I | 1 |
| Fischer, S | 3 |
| Thieme, R | 3 |
| Santos, AN | 2 |
| Sun, Y | 1 |
| Wen, X | 1 |
| Zhao, Y | 1 |
| Shen, T | 1 |
| Liu, Z | 1 |
| Gao, H | 1 |
| Qiu, S | 1 |
| Plösch, T | 1 |
| Seyring, S | 1 |
| Haucke, E | 1 |
| Knelangen, JM | 1 |
| Franzén, S | 1 |
| Friederich-Persson, M | 1 |
| Fasching, A | 1 |
| Hansell, P | 1 |
| Nangaku, M | 1 |
| Palm, F | 1 |
| Ovechkin, AO | 1 |
| Vaykshnorayte, MA | 1 |
| Sedova, K | 1 |
| Shumikhin, KV | 1 |
| Arteyeva, NV | 1 |
| Azarov, JE | 1 |
| Soliman, ND | 1 |
| El-naggar, D | 1 |
| Shafei, A | 1 |
| Rose, KL | 1 |
| Watson, AJ | 1 |
| Drysdale, TA | 1 |
| Cepinskas, G | 1 |
| Chan, M | 1 |
| Rupar, CA | 1 |
| Fraser, DD | 1 |
| Nolasco, EL | 1 |
| Zanoni, FL | 1 |
| Nunes, FP | 1 |
| Ferreira, SS | 1 |
| Freitas, LA | 1 |
| Silva, MC | 1 |
| Martins, JO | 1 |
| Novoselova, EG | 1 |
| Glushkova, OV | 1 |
| Lunin, SM | 1 |
| Khrenov, MO | 1 |
| Novoselova, TV | 1 |
| Parfenyuk, SB | 1 |
| Fesenko, EE | 1 |
| Qiu, G | 1 |
| Tian, W | 1 |
| Huan, M | 1 |
| Chen, J | 3 |
| Fu, H | 1 |
| Heylmann, ASA | 1 |
| Canever, L | 1 |
| Gress, K | 1 |
| Gomes, ST | 1 |
| Fachim, I | 1 |
| Michels, C | 1 |
| Stopassoli, GC | 1 |
| Mastella, GA | 1 |
| Steckert, AV | 1 |
| Damiani, AP | 1 |
| de Andrade, VM | 1 |
| Quevedo, J | 1 |
| Zugno, AI | 1 |
| Yu, X | 1 |
| Park, BH | 1 |
| Wang, MY | 1 |
| Wang, ZV | 1 |
| Unger, RH | 1 |
| Gusdon, AM | 2 |
| Thayer, TC | 1 |
| Mathews, CE | 3 |
| Clements, RT | 1 |
| Sodha, NR | 1 |
| Feng, J | 1 |
| Boodhwani, M | 1 |
| Liu, Y | 1 |
| Mieno, S | 1 |
| Khabbaz, KR | 1 |
| Bianchi, C | 1 |
| Sellke, FW | 1 |
| Zhang, Z | 1 |
| Jiang, J | 1 |
| Yu, P | 1 |
| Zeng, X | 1 |
| Larrick, JW | 1 |
| Wang, Y | 1 |
| Nagib, PR | 1 |
| Gameiro, J | 1 |
| Stivanin-Silva, LG | 1 |
| de Arruda, MS | 1 |
| Villa-Verde, DM | 1 |
| Savino, W | 1 |
| Verinaud, L | 1 |
| Neshati, Z | 1 |
| Matin, MM | 1 |
| Bahrami, AR | 1 |
| Moghimi, A | 1 |
| Gupta, S | 1 |
| Chattopadhyay, T | 1 |
| Pal Singh, M | 1 |
| Surolia, A | 1 |
| Ramin, N | 2 |
| Schmidt, T | 1 |
| Lee, JH | 1 |
| Yang, SH | 1 |
| Oh, JM | 1 |
| Lee, MG | 1 |
| Wang, J | 1 |
| Wan, R | 1 |
| Mo, Y | 1 |
| Zhang, Q | 1 |
| Sherwood, LC | 1 |
| Chien, S | 1 |
| Rendon, DA | 1 |
| Alvarez-Bustamante, JA | 1 |
| Roganović, J | 1 |
| Radenković, M | 1 |
| Tanić, N | 2 |
| Petrović, N | 1 |
| Stojić, D | 1 |
| Mühleck, B | 1 |
| Liu, S | 1 |
| Wang, W | 1 |
| Luo, XM | 1 |
| Ye, B | 1 |
| Linke, A | 1 |
| Zhao, G | 1 |
| Recchia, FA | 1 |
| Williams, J | 1 |
| Xu, X | 1 |
| Hintze, TH | 1 |
| Gai, W | 1 |
| Schott-Ohly, P | 1 |
| Schulte im Walde, S | 1 |
| Gleichmann, H | 1 |
| Federiuk, IF | 1 |
| Casey, HM | 1 |
| Quinn, MJ | 1 |
| Wood, MD | 1 |
| Ward, WK | 1 |
| Sailaja Devi, MM | 1 |
| Das, UN | 3 |
| Suresh, Y | 1 |
| Eventov-Friedman, S | 1 |
| Tchorsh, D | 1 |
| Katchman, H | 1 |
| Shezen, E | 1 |
| Aronovich, A | 1 |
| Hecht, G | 1 |
| Dekel, B | 1 |
| Rechavi, G | 1 |
| Blazar, BR | 1 |
| Feine, I | 1 |
| Tal, O | 1 |
| Freud, E | 1 |
| Reisner, Y | 1 |
| Liang, W | 1 |
| Mao, Y | 1 |
| Li, H | 1 |
| Yang, Y | 1 |
| Tan, H | 1 |
| Hinke, SA | 1 |
| Okamoto, H | 3 |
| Sandler, S | 2 |
| Andersson, A | 1 |
| Yamamoto, H | 1 |
| Mrozikiewicz, A | 1 |
| Kiełczewska-Mrozikiewicz, D | 1 |
| Lowicki, Z | 1 |
| Chmara, E | 1 |
| Korzeniowska, K | 1 |
| Mrozikiewicz, PM | 1 |
| Helqvist, S | 1 |
| Herse, P | 1 |
| Hooker, B | 1 |
| Brand, CL | 1 |
| Jørgensen, PN | 1 |
| Svendsen, I | 1 |
| Holst, JJ | 1 |
| Pusztai, P | 1 |
| Prechl, J | 1 |
| Somogyi, A | 1 |
| Szaleczky, E | 1 |
| Fehér, J | 1 |
| Matsuzaki, T | 1 |
| Nagata, Y | 1 |
| Kado, S | 1 |
| Uchida, K | 1 |
| Hashimoto, S | 1 |
| Yokokura, T | 1 |
| Ohno, T | 1 |
| Kitoh, J | 1 |
| Yamashita, K | 1 |
| Ichikawa, Y | 1 |
| Horio, F | 1 |
| Terada, M | 1 |
| Tanaka, S | 1 |
| Namikawa, T | 1 |
| Ho, E | 3 |
| Chen, G | 2 |
| Bray, TM | 3 |
| Graser, RT | 1 |
| Savinov, A | 1 |
| Serreze, DV | 1 |
| Leiter, EH | 1 |
| Krishna Mohan, I | 1 |
| Quan, N | 1 |
| Tsai, YH | 1 |
| Lai, W | 1 |
| Matas, AJ | 1 |
| Sutherland, DE | 1 |
| Steffes, MW | 1 |
| Najarian, JS | 1 |
| Goto, Y | 1 |
| Pipeleers, D | 1 |
| Welsh, N | 1 |
| Tarui, S | 1 |
| Yamada, K | 1 |
| Hanafusa, T | 1 |
| Christlieb, AR | 1 |
8 reviews available for alloxan and Autoimmune Diabetes
| Article | Year |
|---|---|
Role of increased ROS dissipation in prevention of T1D.
Topics: Alloxan; Animals; Cytoprotection; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug R | 2008 |
Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus.
Topics: Alloxan; Animals; Area Under Curve; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; | 2010 |
Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Disease Models, Animal; Insulin; Rats | 2004 |
Finding GAD: early detection of beta-cell injury.
Topics: Alloxan; Animals; Biomarkers; Cell Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glut | 2007 |
Interleukin 1 beta-mediated destruction of pancreatic beta-cells in vitro. A model of beta-cell destruction in insulin-dependent diabetes mellitus?
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Humans; Interleukin-1; | 1994 |
Islet transplantation.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes M | 1977 |
Purified islet cells in diabetes research.
Topics: Alloxan; Animals; Antigens, Surface; Cell Separation; Cells, Cultured; Cyclic AMP; Diabetes Mellitus | 1986 |
Diabetes and hypertensive vascular disease. Mechanisms and treatment.
Topics: Alloxan; Angiotensin II; Animals; Blood Volume; Diabetes Complications; Diabetes Mellitus; Diabetes | 1973 |
71 other studies available for alloxan and Autoimmune Diabetes
| Article | Year |
|---|---|
Preclinical model of type 1 diabetes and myocardial ischemia/reperfusion injury in conscious rabbits-demonstration of cardioprotection with rapamycin.
Topics: Alloxan; Animals; Apoptosis; Balloon Occlusion; Cardiotonic Agents; Diabetes Mellitus, Experimental; | 2021 |
Attenuation of hyperglycemia and amadori products by aminoguanidine in alloxan-diabetic rabbits occurs via enhancement in antioxidant defenses and control of stress.
Topics: Alloxan; Animals; Antioxidants; Case-Control Studies; Catalase; Diabetes Mellitus, Experimental; Dia | 2022 |
Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists.
Topics: Adipose Tissue; Alloxan; Animals; Blood Glucose; CHO Cells; Cricetulus; Diabetes Mellitus, Experimen | 2022 |
A novel in vitro approach to test the effectiveness of fish oil in ameliorating type 1 diabetes.
Topics: Alloxan; Diabetes Mellitus, Type 1; Fish Oils; Glucose; Humans; Insulin; Pilot Projects; RNA, Messen | 2022 |
A bovine milk-derived peptide ameliorates alloxan-injured pancreatic β cells through IRS2/PI3K/Akt signaling.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Insulin | 2022 |
Induction of Type I Diabetes Mellitus in Beagle Dogs Using Alloxan and Streptozotocin.
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dogs; Insulin; Strepto | 2022 |
All-trans retinoic acid improves pancreatic cell proliferation on induced type 1 diabetic rats.
Topics: Alloxan; Animals; Antioxidants; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; | 2020 |
Antidiabetic and hypolipidemic potentials of
Topics: Alloxan; Amylases; Animals; Antioxidants; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; | 2022 |
Biogenic integrated ZnO/Ag nanocomposite: Surface analysis and in vivo practices for the management of type 1 diabetes complications.
Topics: Alloxan; Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1 | 2020 |
The synergistic promotion of osseointegration by nanostructure design and silicon substitution of hydroxyapatite coatings in a diabetic model.
Topics: Alloxan; Animals; Coated Materials, Biocompatible; Diabetes Mellitus, Experimental; Diabetes Mellitu | 2020 |
Embryonic fatty acid metabolism in diabetic pregnancy: the difference between embryoblasts and trophoblasts.
Topics: Alloxan; Animals; Blastocyst; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Embryo, Ma | 2020 |
Exploring and applying the substrate promiscuity of a C-glycosyltransferase in the chemo-enzymatic synthesis of bioactive C-glycosides.
Topics: Alloxan; Aloe; Animals; Biocatalysis; Blood Glucose; Cloning, Molecular; Diabetes Mellitus, Experime | 2020 |
Silymarin Attenuates Hepatic and Pancreatic Redox Imbalance Independent of Glycemic Regulation in the Alloxan-induced Diabetic Rat Model.
Topics: Alloxan; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Liver; O | 2020 |
Therapeutic role of Rauwolfia serpentina in minimizing the risk of glycosylation and associated biomarkers in experimentally induced type 1 diabetic mice.
Topics: Alloxan; Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glycosylat | 2021 |
Insulin- and cholic acid-loaded zein/casein-dextran nanoparticles enhance the oral absorption and hypoglycemic effect of insulin.
Topics: Administration, Oral; Alloxan; Animals; Biological Availability; Caseins; Cholic Acid; Dextrans; Dia | 2021 |
Adiponectin stimulates lipid metabolism via AMPK in rabbit blastocysts.
Topics: Acetyl-CoA Carboxylase; Adiponectin; Alloxan; AMP-Activated Protein Kinases; Animals; Blastocyst; Ca | 2017 |
Endogenous Reprogramming of Alpha Cells into Beta Cells, Induced by Viral Gene Therapy, Reverses Autoimmune Diabetes.
Topics: Alloxan; Animals; Blood Glucose; Cellular Reprogramming; Dependovirus; Diabetes Mellitus, Experiment | 2018 |
Histomorphometric evaluation of bone regeneration using autogenous bone and beta-tricalcium phosphate in diabetic rabbits.
Topics: Alloxan; Animals; Bone Regeneration; Bone Transplantation; Calcium Phosphates; Diabetes Mellitus, Ex | 2016 |
ANTIDIABETIC AND ANTIDYSLIPIDEMIC EFFECTS OF HELIOTROPIUM STRIGOSUM IN RAT MODELS OF TYPE I AND TYPE II DIABETES.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabete | 2016 |
Involvement of inducible nitric oxide synthase and estrogen receptor ESR2 (ERβ) in the vascular dysfunction in female type 1 diabetic rats.
Topics: Alloxan; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Endothelium, Va | 2019 |
Extended Duration of Hyperglycemia Result in Human-Like Corneal Nerve Lesions in Mice With Alloxan- and Streptozotocin-Induced Type 1 Diabetes.
Topics: Alloxan; Animals; Cornea; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Neuro | 2018 |
Ameliorative effect of Myristica fragrans (nutmeg) extract on oxidative status and histology of pancreas in alloxan induced diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Male; M | 2020 |
Antidiabetic and antidyslipidemic potential of Echinops echinatus in rat models of type I and type II diabetes.
Topics: Alloxan; Animals; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2019 |
cAMP-responsive element binding protein: a vital link in embryonic hormonal adaptation.
Topics: Activating Transcription Factor 1; Activating Transcription Factor 3; Adiponectin; Alloxan; Animals; | 2013 |
Yeast exposure in the preparation of steamed rehmannia root improving its effects on alloxan-induced diabetic rats.
Topics: 6-Ketoprostaglandin F1 alpha; Aldosterone; Alloxan; Angiotensin II; Animals; Behavior, Animal; Blood | 2013 |
Maternal diabetes leads to unphysiological high lipid accumulation in rabbit preimplantation embryos.
Topics: Alloxan; Animals; Blastocyst; Blood Glucose; Diabetes Mellitus, Type 1; Disease Models, Animal; Fatt | 2014 |
Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes.
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies | 2014 |
Functional role of myocardial electrical remodeling in diabetic rabbits.
Topics: Alloxan; Animals; Animals, Inbred Strains; Arrhythmias, Cardiac; Diabetes Mellitus, Type 1; Diabetic | 2015 |
Investigation of antidiabetic action of Antidesma bunius extract in type 1 diabetes.
Topics: Alloxan; Amylases; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Me | 2015 |
Simulated diabetic ketoacidosis therapy in vitro elicits brain cell swelling via sodium-hydrogen exchange and anion transport.
Topics: Alloxan; Animals; Anions; Brain; Brain Edema; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2015 |
Insulin Modulates Liver Function in a Type I Diabetes Rat Model.
Topics: Alloxan; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Type 1; Hypoglycemic Agents; Insulin, | 2015 |
Signaling, stress response and apoptosis in pre-diabetes and diabetes: restoring immune balance in mice with alloxan-induced type 1 diabetes mellitus.
Topics: Alloxan; Animals; Antioxidants; Apoptosis; Cytokines; Diabetes Mellitus, Type 1; Humans; Insulin-Sec | 2016 |
Formononetin exhibits anti-hyperglycemic activity in alloxan-induced type 1 diabetic mice.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2017 |
Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia.
Topics: Alloxan; Animals; Behavior, Animal; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
Making insulin-deficient type 1 diabetic rodents thrive without insulin.
Topics: Alloxan; Animals; Diabetes Complications; Diabetes Mellitus, Type 1; Down-Regulation; Glucagon; Insu | 2008 |
Impaired coronary microvascular dilation correlates with enhanced vascular smooth muscle MLC phosphorylation in diabetes.
Topics: Alloxan; Animals; Coronary Vessels; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diab | 2009 |
Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment.
Topics: Alloxan; Animals; Blood Glucose; Cytoprotection; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2009 |
Thymic microenvironmental alterations in experimentally induced diabetes.
Topics: Alloxan; Animals; Atrophy; Body Weight; Cell Movement; Cell Survival; Chemokine CXCL12; Chemokines, | 2010 |
Differentiation of mesenchymal stem cells to insulin-producing cells and their impact on type 1 diabetic rats.
Topics: Alloxan; Animals; Cell Differentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; | 2010 |
Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus.
Topics: Adipocytes; Alloxan; Amyloid; Animals; Blood Glucose; Cattle; Cells, Cultured; Congo Red; Diabetes M | 2010 |
Maternal diabetes impairs gastrulation and insulin and IGF-I receptor expression in rabbit blastocysts.
Topics: Alloxan; Animals; Apoptosis; Blastocyst; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Me | 2010 |
Creating a long-term diabetic rabbit model.
Topics: Alloxan; Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; D | 2010 |
Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes?
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease | 2011 |
Impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated parotid artery of the alloxan-induced diabetic rabbit.
Topics: Acetylcholine; Alloxan; Animals; Arteries; Bradykinin; Cyclooxygenase Inhibitors; Diabetes Mellitus, | 2011 |
Role of genetics in resistance to type 1 diabetes.
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; DNA-Binding Proteins; | 2011 |
Insulin growth factor adjustment in preimplantation rabbit blastocysts and uterine tissues in response to maternal type 1 diabetes.
Topics: Alloxan; Animals; Blastocyst; Cell Differentiation; Diabetes Mellitus, Experimental; Diabetes Mellit | 2012 |
[Chemically induced (streptozotocin-alloxan) diabetes mellitus in dogs].
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal | 2000 |
Shift in metabolic substrate uptake by the heart during development of alloxan-induced diabetes.
Topics: 3-Hydroxybutyric Acid; Alloxan; Animals; Blood Glucose; Blood Pressure; Body Weight; Carbon Dioxide; | 2003 |
Differential target molecules for toxicity induced by streptozotocin and alloxan in pancreatic islets of mice in vitro.
Topics: Alloxan; Animals; Arginine; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2004 |
Effect of prostaglandins against alloxan-induced diabetes mellitus.
Topics: Alloxan; Alprostadil; Animals; Antioxidants; Blood Glucose; Body Weight; Catalase; Ceruloplasmin; Di | 2006 |
Differential effect of saturated, monounsaturated, and polyunsaturated fatty acids on alloxan-induced diabetes mellitus.
Topics: Alloxan; Animals; Arachidonic Acid; Blood Glucose; Body Weight; Catalase; Ceruloplasmin; Diabetes Me | 2006 |
Embryonic pig pancreatic tissue transplantation for the treatment of diabetes.
Topics: Abatacept; Agammaglobulinaemia Tyrosine Kinase; Alloxan; Animals; Blood Glucose; CD40 Ligand; Diabet | 2006 |
Hepatic glucokinase activity is the primary defect in alloxan-induced diabetes of mice.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; | 2009 |
[Vasoactive intestinal polypeptide(VIP)- and insulin-producing cells--molecular biology, physiology and pathology].
Topics: Adenoma, Islet Cell; Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; D | 1984 |
Survival of intrasplenically implanted islets in mice with experimental insulitis and hyperglycemia.
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Graft Survival | 1982 |
DNA strand breaks and poly(ADP-ribose) synthetase activation in pancreatic islets--a new aspect to development of insulin-dependent diabetes and pancreatic B-cell tumors.
Topics: Adenoma, Islet Cell; Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; D | 1983 |
Blood levels of alloxan in children with insulin-dependent diabetes mellitus.
Topics: Adolescent; Alloxan; Case-Control Studies; Child; Diabetes Mellitus, Type 1; Free Radicals; Humans | 1994 |
Corneal edema recovery dynamics in diabetes: is the alloxan induced diabetic rabbit a useful model?
Topics: Adolescent; Adult; Alloxan; Animals; Contact Lenses, Hydrophilic; Cornea; Corneal Edema; Diabetes Me | 1994 |
Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits.
Topics: Alloxan; Animals; Antibodies, Monoclonal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes M | 1996 |
[Experimental models in research of the pathomechanism of diabetes mellitus].
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal | 1996 |
Effect of oral administration of Lactobacillus casei on alloxan-induced diabetes in mice.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diet Th | 1997 |
Toxin-induced IDDM (insulin dependent diabetes mellitus) in the musk shrew.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease | 1998 |
Supplementation of N-acetylcysteine inhibits NFkappaB activation and protects against alloxan-induced diabetes in CD-1 mice.
Topics: Acetylcysteine; Administration, Oral; Alloxan; Animals; Blood Glucose; Cyclic N-Oxides; Diabetes Mel | 1999 |
Alpha-phenyl-tert-butylnitrone (PBN) inhibits NFkappaB activation offering protection against chemically induced diabetes.
Topics: Alloxan; Animals; Cyclic N-Oxides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Free | 2000 |
Unusual resistance of ALR/Lt mouse beta cells to autoimmune destruction: role for beta cell-expressed resistance determinants.
Topics: Adoptive Transfer; Alloxan; Animals; Autoimmunity; Bone Marrow Transplantation; Cell Death; Chimera; | 2001 |
Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids.
Topics: Alloxan; Animals; Antioxidants; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2001 |
Dietary zinc supplementation inhibits NFkappaB activation and protects against chemically induced diabetes in CD1 mice.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dietary | 2001 |
[Experimental animal models of diabetes mellitus].
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 1991 |
Mechanisms of pancreatic B-cell degeneration during the course of insulin-dependent diabetes mellitus.
Topics: Alloxan; Animals; Autoimmune Diseases; Chromosomes, Human, 6-12 and X; Diabetes Mellitus, Experiment | 1985 |
Animal models utilized in the research of diabetes mellitus--with special reference to insulitis-associated diabetes.
Topics: Alloxan; Animals; Chelating Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diab | 1987 |
The role of poly(ADP-ribose) synthetase in the development of insulin-dependent diabetes and islet B-cell regeneration.
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; DNA Repair; DNA Replic | 1985 |